ProCE Banner Activity

Integration of Novel Antibody–Drug Conjugates in Advanced HER2-Low, Hormone Receptor–Positive, and Triple-Negative Breast Cancer

PDF

Download this poster to learn more about outcomes from an online educational program to understand the current clinical knowledge and use of sacituzumab govitecan and trastuzumab deruxtecan by healthcare professionals in the management of patients with advanced breast cancer.

Released: November 13, 2024

Expiration: November 12, 2025

Share

Faculty

Komal Jhaveri

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Melinda Telli

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Disclosure

Primary Author

Komal Jhaveri, MD, FACP

Patricia and James Cayne Chair for Junior Faculty
Associate Attending Physician
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

Komal Jhaveri, MD, FACP: consultant/advisor: AbbVie, AstraZeneca, Blueprint, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Genentech, Gilead, Jounce, Loxo Oncology, Menarini, Novartis, Olema Oncology, Pfizer, Scorpion Therapeutics, Seagen, Stemline Therapeutics, Sun Pharma Advanced Research Company, Taiho Oncology; researcher: AstraZeneca, Debiopharm, Genentech, Gilead, Loxo Oncology, Merck, Novartis, Pfizer, Puma Biotechnology, Scorpion Therapeutics, Zymeworks.

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Melinda Telli, MD: consultant/advisor/speaker: AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Genentech, GlaxoSmithKline, Guardant, Merck, Natera, Novartis, Pfizer, RefleXion, Replicate, Sanofi Aventis; data safety monitoring committee: Gilead, G1 Therapeutics.

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, ARC Therapeutics, Artios, Arvinas, AstraZeneca, Bayer, BeyondSpring, BioNTech, Blueprint Medicines, Bristol Myers Squibb/Systimmune, Circle Pharma, Cullinan, CytomX, Daiichi Sankyo, eFFECTOR, Eisai, Genentech/Roche, Gilead, Hengrui, Incyte, Jazz, Johnson & Johnson/AMBRX, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Natera, Novartis, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Sumitovant, Tango, Umoja Biopharma, Zentalis, Zuellig, Zymeworks; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb/Systimmune, Cyclacel, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Menarini/Stemline, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi, Seattle Genetics.